Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 27, 2020

View Archived Issues

Cross-reactive immunity helps antitumor response

How antidepressants inhibit fibrosis

Interim results from a phase I trial of FixVac RNA vaccine in patients with advanced melanoma

BBT-032 inhibits growth of the SARS-CoV-2 virus in preclinical studies

Expression Therapeutics developing gene therapy candidate for FHL3

TLR adjuvant makes for longer immune responses

Albireo presents new SLC10A2 and/or SLC10A1 inhibitors

DNA polymerase theta inhibitors identified at Ideaya Biosciences

Lilly discovers KCNQ2/3 channel activators

Capulus Therapeutics synthesizes new SREBP inhibitors

New IL-17A/IL-17RA interaction inhibitors patented by DiCE Molecules

Oncology Venture to advance stenoparib into clinical trials for COVID-19

MK-4710: a new potent, selective, brain-penetrant M4R PAM suitable for clinical development

Debiopharm begins phase I study of Debio-1124 for small cell carcinoma

Novartis details development of best-in-class LTA4 hydrolase inhibitor LYS-006

Conditional E.U. approval for Idefirix for highly sensitized kidney transplant patients

FDA approves Winlevi for acne

New phase II study investigates pelareorep with retifanlimab for triple-negative breast cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 5, 2025.
MicroRNAs in circulating extracellular vesicles as IPF biomarkers
BioWorld Science
MicroRNAs (miRNAs) are small noncoding RNAs gaining increasing attention due to their crucial role in gene expression regulation and influence in various cellular...
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Study identifies CAND1 as therapeutic target in hepatoblastoma
BioWorld Science
Hepatoblastoma is the most common liver cancer during childhood, with limited therapeutic options in aggressive or relapsed cases. NEDDylation is a...